Advertisement
Original article| Volume 108, ISSUE 1, P7-10, July 1986

Human and canine ventricular vasoactive intestinal polypeptide: Decrease with heart failure

  • Donald V. Unverferth
    Correspondence
    Reprint requests: Donald V. Unverferth, M.D., 657 Means Hall, 1655 Upham Dr., Columbus, OH 43210.
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Thomas M. O'Dorisio
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Michael M. Miller
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Barry F. Uretsky
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Raymond D. Magorien
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Carl V. Leier
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Mark E. Thompson
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
  • Robert L. Hamlin
    Affiliations
    From the Divisions of Cardiology and Endocrinology, Department of Medicine, Columbus, Ohio, U.S.A.

    From the Department of Veterinary Physiology, Ohio State University, Columbus, Ohio, U.S.A.

    From the Division of Cardiology, Department of Medicine, University of Pittsburgh Pittsburgh, Pennsylvania, U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Vasoactive intestinal polypeptide (VIP) is a systemic and coronary vasodilator that may have positive inotropic properties. Myocardial levels of VIP were assayed before and after the development of heart failure in two canine models. In the first, cobalt cardiomyopathy was induced in eight dogs; VIP (by radio-immunoassay) decreased from 35 ± 11 pg/mg protein (mean ± SD) to 5 ± 4 pg/ mg protein (P < 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 ± 7 to 11 ± 4 pg/mg protein (P < 0.05). In addition, VIP content of left ventricular muscle of resected falling hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 ± 1.9 pg/mg protein). The other patients undergoing transplantation had an average election fraction of 17% ± 6% and a VIP level of 8.8 ± 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% ± 10%) had a VIP concentration of 14.1 ± 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P < 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P < 0.05) between the tissue concentrations of VIP and norepinephrine was noted. Reduction of VIP is part of the pathologic process of cardiac failure, but the role of VIP and the mechanism of the reduction remain to be determined.

      Abbreviations:

      %ΔD (percent change in systole of left ventricular minor axis dimension), dP/dt max (maximum rate of rise in ventricular pressure), VIP (vasoactive intestinal polypeptide)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Said SI
        • Mutt V
        Polypeptide with broad biological activity: isolation from small intestine.
        Science. 1970; 169: 1217-1218
        • Said SI
        • Mutt V
        Isolation from porcine intestinal wall of a vasoactive octocosa peptide related to secretin and glucagon.
        Eur J Biochem. 1972; 28: 199-204
        • Said SI
        • Mutt V
        Potent peripheral and splanchnic vasodilator peptide from normal gut.
        Nature. 1970; 225: 863-864
        • Yoshida T
        • Geumei AM
        • Schmitt RJ
        • Said SI
        Vasoactive intestinal polypeptide: a potent coronary vasodilator (Abstr).
        in: 4th ed. Fed Proc. 33. 1974: 378
        • Said SI
        • Bosher LP
        • Spath JA
        • Kontos HA
        Positive inotropic action of newly isolated vasoactive intestinal polypeptide (VIP) (Abstr).
        Clin Res. 1972; 20: 29
        • Giachetti A
        • Said SI
        • Reynolds RC
        • Koniges FC
        Vasoactive intestinal polypeptide in brain: localization in and release from isolated nerve terminals.
        in: 4th ed. Proc Natl Acad Sci USA. 74. 1977
        • Unverferth DV
        • O'Dorisio TM
        • Muir WW
        • et al.
        Effect of vasoactive intestinal polypeptide on the canine cardiovascular system.
        J Lab Clin Med. 1985; 106: 542-550
        • Weihe E
        • Reinecke M
        Peptidergic innervation of the mammalian sinus nodes: vasoactive intestinal polypeptide, neurotensin, substance P.
        Neurosci Lett. 1981; 26: 283-288
        • Unverferth DV
        • Croskery RW
        • Leier CV
        • et al.
        Canine cobalt cardiomyopathy: a model for the study of heart failure.
        Am J Vet Res. 1983; 44: 989-995
        • Gaginella TS
        • Mekhjian HS
        • O'Dorisio TM
        Vasoactive intestinal peptide: quantification by radioimmunoassay in isolated cells, mucosa, and muscle of the hamster intestine.
        Gastroenterology. 1978; 74: 718-721
        • Lowry OH
        • Rosebrough NJ
        • Farr AL
        • Randall RJ
        Protein measurement with the Folin phenol reagent.
        J Biol Chem. 1951; 193: 265-275
        • Peuler JD
        • Johnson GA
        Simultaneous single inotrope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.
        Life Sci. 1977; 21: 625-636
        • Bryant MG
        • Polak MM
        • Modlin I
        • Bloom SR
        • Albuquerque RH
        • Pearse AGE
        Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance.
        Lancet. 1976; 1: 991-993
        • Gaginella TS
        • Hubel KA
        • O'Dorisio TM
        Effects of vasoactive intestinal peptide on intestinal chloride secretion.
        in: Said SI Vasoactive intestinal peptide. Raven Press, New York1982: 211
        • Dingle JT
        • Heath JC
        • Webb M
        • Daniel M
        The biological action of cobalt and other metals. II. The mechanism of the respiratory inhibition produced by cobalt in mammalian tissues.
        Biochim Biophys Acta. 1962; 65: 34-36
        • Heggtveit HA
        • Grice HC
        • Wiberg GS
        Cobalt cardiomyopathy.
        Pathol Microbiol. 1970; 34: 110-113
        • Webb M
        The biological action of cobalt and other metals. IV. Inhibition of α-oxoglutarate dehydrogenase.
        Biochim Biophys Acta. 1964; 89: 431-446
        • Knieriem HJ
        • Herbertz G
        Electron microscopic findings, and photometric and activation-analytical results in experimental cardiac insufficiency caused by cobaltous chloride.
        Virchows Arch [Cell Pathol]. 1969; 2: 32-46
        • Pigram WJ
        • Fuller W
        • Hamilton LD
        Stereochemistry of intercalation: interaction of daunomycin with DNA.
        Nature. 1972; 235: 17-19
        • Goodman J
        • Hochstein P
        Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and daunomycin.
        Biochem Biophys Res Commun. 1977; 77: 797-803
        • Mimnaugh EG
        • Trush MA
        • Gram TE
        Stimulation by Adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation.
        Biochem Pharmacol. 1981; 30: 2797-2804
        • Unverferth DV
        • Fertel RH
        • Thomas J
        • et al.
        The evolution of beta adrenergic dysfunction during the induction of canine cobalt cardiomyopathy.
        Cardiovasc Res. 1984; 18: 44-50
        • Weiss MB
        • Ellis K
        • Sciacca RR
        • Johnson LL
        • Schmidt DH
        • Cannon PJ
        Myocardial blood flow in congestive and hypertrophic cardiomyopathy.
        Circulation. 1976; 54: 484-494
        • Chidsey CB
        • Braunwald E
        • Morrow AG
        Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure.
        Am J Med. 1965; 39: 442-451
        • Weinshilboum RM
        • Thoa NB
        • Johnson DG
        • Kapin IJ
        • Axelrod J
        Proportional release of norepinephrine and dopamine-β-hydroxylase from sympathetic nerves.
        Science. 1971; 174: 1349-1351
        • Sole MJ
        • Kamble RB
        • Hussain MN
        A possible change in the rate limiting step for cardiac norepinephrine synthesis in the cardiomyopathic Syrian hamster.
        Circ Res. 1977; 41: 814-817
        • Petch MC
        • Nayler WG
        Uptake of catecholamines by human cardiac muscle in vitro.
        Br Heart J. 1979; 41: 336-339